Davidson Michael H. (CIK 1573785) reported 15 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-09-15). Recent activity: Buy NAMS (10,000 shares), Buy NAMS (443,707 shares), Sell NAMS (443,707 shares), Buy NAMS (64,708 shares), Sell NAMS (61,547 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-15 | NewAmsterdam Pharma Co N.V. (NAMS) | Chief Executive Officer | Buy | 10,000 | $226,500 |
| 2026-03-02 | NewAmsterdam Pharma Co N.V. (NAMS) | Chief Executive Officer | Buy | 443,707 | $0 |
| 2026-03-02 | NewAmsterdam Pharma Co N.V. (NAMS) | Chief Executive Officer | Sell | 443,707 | $14.8M |
| 2026-02-26 | NewAmsterdam Pharma Co N.V. (NAMS) | Chief Executive Officer | Buy | 64,708 | $0 |
| 2026-02-26 | NewAmsterdam Pharma Co N.V. (NAMS) | Chief Executive Officer | Sell | 61,547 | $2.2M |
| 2026-02-26 | NewAmsterdam Pharma Co N.V. (NAMS) | Chief Executive Officer | Sell | 3,161 | $115,250 |
| 2026-02-26 | NewAmsterdam Pharma Co N.V. (NAMS) | Chief Executive Officer | Buy | 58,253 | $0 |
| 2026-02-26 | NewAmsterdam Pharma Co N.V. (NAMS) | Chief Executive Officer | Sell | 46,517 | $1.6M |
| 2026-02-26 | NewAmsterdam Pharma Co N.V. (NAMS) | Chief Executive Officer | Sell | 10,436 | $375,279 |
| 2026-02-26 | NewAmsterdam Pharma Co N.V. (NAMS) | Chief Executive Officer | Sell | 1,300 | $47,684 |
| 2026-02-26 | NewAmsterdam Pharma Co N.V. (NAMS) | Chief Executive Officer | Buy | 183,332 | $0 |
| 2026-02-26 | NewAmsterdam Pharma Co N.V. (NAMS) | Chief Executive Officer | Sell | 165,408 | $5.6M |
| 2026-02-26 | NewAmsterdam Pharma Co N.V. (NAMS) | Chief Executive Officer | Sell | 17,924 | $617,303 |
| 2026-01-09 | NewAmsterdam Pharma Co N.V. (NAMS) | Chief Executive Officer | Sell | 11,582 | $0 |
| 2026-01-09 | NewAmsterdam Pharma Co N.V. (NAMS) | Chief Executive Officer | Buy | 81,000 | $0 |
来源：SEC Form 4 申报文件 · 截至 2026-09-15